The oligonucleotide synthesis market size is projected to grow by USD 4.75 billion at a CAGR of 17.4% between 2024 and 2029. The oligonucleotide synthesis market is witnessing rapid expansion due to the increasing shift toward RNA-based therapeutics. This growth is driven by advancements in RNA technology and the potential of RNA therapeutics to address diseases such as genetic disorders and cancer.Another key trend transforming the market is the integration of artificial intelligence (AI) and automation in oligonucleotide synthesis. AI-driven algorithms improve efficiency, reduce errors, and lower production costs.However, regulatory challenges continue to pose hurdles for market expansion. Stringent regulatory requirements and lengthy approval processes hinder the commercialization of oligonucleotide therapeutics. Ensuring safety and efficacy remains a critical factor for market approval.
For more details about the industry, get the PDF sample report for free
North America
Canada
US
Europe
Germany
UK
Asia
China
Rest of World (ROW)
The PCR primers segment is expected to register significant growth during the forecast period.
Oligonucleotide synthesis plays a crucial role in the production of PCR primers, which are essential for gene expression analysis, DNA sequencing, mutation detection, and genotyping. Many companies provide custom PCR primer design and synthesis services, allowing researchers to specify target DNA sequences, primer lengths, and modifications.
PCR primers are also widely used in therapeutics and diagnostics, particularly in CRISPR gene editing, cancer therapy, and rare disease research. Diseases such as Down syndrome and Charcot-Marie-Tooth disease (linked to IGHMBP2 gene mutations) are areas where synthesized oligonucleotides are applied.
In synthetic biology and genome projects, oligonucleotides support various applications, including:
The PCR primers segment was valued at USD 546.90 million in 2019, with steady growth observed through the forecast period.
The rising adoption of RNA-based therapeutics is fueling demand for custom-designed oligonucleotides. Oligonucleotides serve as DNA and RNA nucleotides, essential for genetic testing, molecular diagnostics, and analytical testing.
Advancements in RNA-based therapeutics, such as mRNA vaccines, antisense oligonucleotides (ASOs), and RNA interference (RNAi) therapies, are driving market demand.
Companies now offer oligonucleotide modifications, including:
These modifications cater to diverse industry needs, particularly in the field of RNA-based therapeutics.
AI-driven algorithms are revolutionizing oligonucleotide synthesis by improving:
AI-based platforms enable parallel synthesis of multiple oligonucleotide sequences, significantly enhancing scalability.
AI automation is also aiding therapeutic applications such as:
Advanced oligonucleotide modification and purification techniques, including polyacrylamide gel electrophoresis, ensure high-quality synthesis for therapeutics and diagnostics.
The complex regulatory landscape for oligonucleotide therapeutics remains a challenge.
Regulatory frameworks, including FDA and EMA guidelines, lack harmonization, making compliance difficult for manufacturers.
The US FDA classifies oligonucleotide drugs as small molecules under the Center for Drug Evaluation and Research (CDER), further complicating approval processes.
Despite their potential in treating diseases such as cancer, Down syndrome, Charcot-Marie-Tooth disease, and cystic fibrosis, regulatory constraints limit market expansion.
Get more details by ordering the complete report
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
